Zobrazeno 1 - 10
of 47
pro vyhledávání: '"N. R. Cutler"'
Publikováno v:
Acta Neurologica Scandinavica. 97:244-250
This study evaluates the activity of SDZ ENA 713, a centrally-selective acetylcholinesterase (AChE) inhibitor, in the cerebral spinal fluid (CSF) of patients with Alzheimer's disease (AD), and its relationship to central and peripheral pharmacokineti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9cafb5bdff0bc36ea64a14687e8a1e6
https://doi.org/10.1111/j.1600-0404.1998.tb00645.x
https://doi.org/10.1111/j.1600-0404.1998.tb00645.x
Publikováno v:
Journal of Neural Transmission. 109:1053-1065
Cholinesterase (ChE) inhibition represents the most efficacious treatment approach for Alzheimer's disease (AD) to date. This multiple-dose study has examined the relationship between inhibition of acetylcholinesterase (AChE) and butyrylcholinesteras
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebc8892a9f497114264335faa7d821bf
https://doi.org/10.1007/s007020200089
https://doi.org/10.1007/s007020200089
Autor:
W S Mullican, B Levy, M T Leibowitz, P D Toth, J J Sramek, N R Cutler, C M Mendel, F G McMahon, E. Rowe, S P Weinstein
Publikováno v:
Journal of Human Hypertension. 16:13-19
Sibutramine is a serotonin-noradrenaline reuptake inhibitor that is effective for long-term weight reduction and maintenance in obese patients when used as an adjunct to dietary and behavioural measures. Because the inhibition of noradrenaline reupta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::137a99ee3228324595bb54793407d88c
https://doi.org/10.1038/sj.jhh.1001299
https://doi.org/10.1038/sj.jhh.1001299
Autor:
B, Gomez-Mancilla, N R, Cutler, M T, Leibowitz, E L, Spierings, J A, Klapper, S, Diamond, J, Goldstein, T, Smith, J R, Couch, J, Fleishaker, N, Azie, D E, Blunt
Publikováno v:
Cephalalgia. 21:727-732
In this randomized, double-blind, placebo-controlled, parallel-group study, patients received a single 50-mg oral dose of a 5-HT(1D) agonist, PNU-142633 (n = 34), or matching placebo (n = 35) during an acute migraine attack. No statistically signific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70f35fbd2ef9c424241a2d961fa45a7
https://doi.org/10.1046/j.1468-2982.2001.00208.x
https://doi.org/10.1046/j.1468-2982.2001.00208.x
Autor:
G. Block, Scott A. Reines, T.V. Olah, D Panebianco, H. Cheng, N. R. Cutler, J. Claghorn, J J Sramek
Publikováno v:
Cephalalgia. 16:113-116
MK-462 is a potent, selective 5HT1D receptor agonist which may be useful in treating acute migraine. We conducted a double-blind placebo-controlled inpatient study to assess the preliminary efficacy and safety of oral doses of MK-462 20 mg ( n = 8) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a72ff5c1b6ececbb50d57c08e76805
https://doi.org/10.1046/j.1468-2982.1996.1602113.x
https://doi.org/10.1046/j.1468-2982.1996.1602113.x
Autor:
R. C. Green, F. P. Zemlan, W. E. Reichman, Piero Antuono, S. R. Cohen, J. E. Shipley, F. J. Huff, M. Alter, J. E. Delagandara, N. R. Cutler, M. A. McDonald, M. L. Crismon
Publikováno v:
Alzheimer Disease & Associated Disorders. 10:93-102
Besipirdine hydrochloride (HP 749) is an indole-substituted analog of 4-aminopyridine. Besipirdine enhances both cholinergic and adrenergic neurotransmission in the central nervous system. The present study examined the efficacy and tolerability of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::262a66ac7bda7112dc076388f04531c2
https://doi.org/10.1097/00002093-199601020-00007
https://doi.org/10.1097/00002093-199601020-00007
Autor:
J. P. Hubble, J J Sramek, Joseph H. Friedman, A Elvin, D Korts, N R Cutler, William C. Koller, Christopher G. Goetz, A Ranhosky
Publikováno v:
Clinical Neuropharmacology. 18:338-347
We evaluated the efficacy, safety, tolerability, and pharmacokinetics of pramipexole, a novel dopamine D2 receptor agonist, in early Parkinson's disease (PD). The study design was a parallel, placebo-controlled trial using an ascending dose of 4.5 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09ced997c7b91fafd35e24acbf381490
https://doi.org/10.1097/00002826-199508000-00006
https://doi.org/10.1097/00002826-199508000-00006
Autor:
M.D. Ferrari, L.A. Paulsgrove, R.L. Davis, A. M. Rapoport, C.J. Alderton, W. H. Visser, N. R. Cutler
Publikováno v:
Neurology. 45:1505-1509
Headache recurrence (HR) may occur within 24 hours in approximately 40% of migraine attacks initially treated successfully with 6 mg subcutaneous (SC) sumatriptan. This may be due to the short plasma half-life of sumatriptan. We studied whether an ad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e71aa77946c18a5719879e69938e0d8a
https://doi.org/10.1212/wnl.45.8.1505
https://doi.org/10.1212/wnl.45.8.1505
Publikováno v:
Anxiety. 1:141-143
L-365,260 is a CCKB antagonist which has been shown to completely prevent CCK-4-induced symptoms of panic attack in single-dose (50 mg) placebo-controlled studies in patients with panic disorder. The present report is data from one site (n = 38) in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3dfbbbdeb3a5e9567a2f82cdd061def9
https://doi.org/10.1002/anxi.3070010308
https://doi.org/10.1002/anxi.3070010308
Autor:
N R, Cutler
Publikováno v:
The Journal of clinical psychiatry. 62
In clinical trials of dopamine-blocking antipsychotics, significant adverse events may occur in healthy volunteers at dose levels that are well tolerated by schizophrenic patients. Because of these differences in tolerability, bioequivalence and phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::962b859b0b31fae1b58f6e49e770deee
https://pubmed.ncbi.nlm.nih.gov/11305842
https://pubmed.ncbi.nlm.nih.gov/11305842